<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2026.1804564</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Exploring sulfur compounds&#x2019; role in inflammation and therapeutic potential</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Iciek</surname><given-names>Ma&#x142;gorzata</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2685256/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Sawa</surname><given-names>Tomohiro</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/583510/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Lauriano</surname><given-names>Eugenia Rita</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2516816/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kota&#x144;ska</surname><given-names>Magdalena</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/355199/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Chair of Medical Biochemistry, Jagiellonian University, Medical College</institution>, <city>Krakow</city>,&#xa0;<country country="pl">Poland</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University</institution>, <city>Kumamoto</city>,&#xa0;<country country="jp">Japan</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina</institution>, <city>Messina</city>,&#xa0;<country country="it">Italy</country></aff>
<aff id="aff4"><label>4</label><institution>Laboratory of Pharmacological Screening, Department of Pharmacodynamics, Jagiellonian University Medical College</institution>, <city>Krakow</city>,&#xa0;<country country="pl">Poland</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Magdalena Kota&#x144;ska, <email xlink:href="mailto:magda.dudek@uj.edu.pl">magda.dudek@uj.edu.pl</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-12">
<day>12</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1804564</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>02</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Iciek, Sawa, Lauriano and Kota&#x144;ska.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Iciek, Sawa, Lauriano and Kota&#x144;ska</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-12">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<kwd-group>
<kwd>hydrogen sulfide</kwd>
<kwd>inflammation</kwd>
<kwd>reactive sulfur species</kwd>
<kwd>sulfur dioxide</kwd>
<kwd>supersulfides</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="5"/>
<page-count count="3"/>
<word-count count="1027"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes notes-type="frontiers-research-topic">
<p>Editorial on the Research Topic <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/research-topics/64997/exploring-sulfur-compounds-role-in-inflammation-and-therapeutic-potential/articles">Exploring sulfur compounds&#x2019; role in inflammation and therapeutic potential</ext-link>
</p>
</notes>
</front>
<body>
<p>Sulfur, long recognized as an essential element for life, has moved from the periphery of environmental science to the center of modern redox biology. Recent research has emphasized the role of reactive sulfur species (RSS), such as hydrogen sulfide (H<sub>2</sub>S), hydropersulfides (RSSH), polysulfides (RSS<sub>n</sub>R) as well as sulfur dioxide (SO<sub>2</sub>) in numerous biological processes (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The main biological mechanism of RSS action is protein persulfidation&#x2014;reversible modification of cysteine -SH groups into -SSH residues (<xref ref-type="bibr" rid="B3">3</xref>). In turn, SO<sub>2</sub>, which is emerging as a novel gasotransmitter can be responsible for protein sulfenylation (-SOH) (<xref ref-type="bibr" rid="B2">2</xref>). Given the participation of RSS in various physiological and pathological pathways, their role in immune homeostasis is being extensively studied (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). This Research Topic of <italic>Frontiers in Immunology</italic> explores the immunomodulatory mechanisms of RSS, bringing together noteworthy research and reviews that elucidate how these species navigate complex signaling pathways to maintain homeostasis. Furthermore, it highlights new avenues for treating chronic and acute inflammatory diseases through regulation of RSS homeostasis.</p>
<p>The review article by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2026.1736794">Chen et&#xa0;al.</ext-link> provides a comprehensive overview of the latest findings regarding the role of RSS in the immune system, highlighting their context-dependent, bidirectional effects governed by cellular redox states, as well as metabolic and inflammatory conditions. Following a general introduction to RSS biosynthesis, chemical properties, and biological importance, the authors focus on the mechanisms regulating key signaling pathways. The authors point out that RSS regulate immune cells through the persulfidation of NF-&#x3ba;B and Keap1, maintain mitochondrial integrity, and control the metabolic switch between glycolysis and mitochondrial respiration. Furthermore, RSS can inhibit inflammation and autoimmune diseases by suppressing Neutrophil Extracellular Traps (NETosis) through the ROS-MAPK-PAD4 signaling cascade. The authors conclude their manuscript by identifying knowledge gaps and challenges, including the specificity of RSS and the dose-response relationship. Moreover, the therapeutic potential of RSS donors for the treatment of immune-related diseases is discussed.</p>
<p>The next excellent review paper, by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1581385">Zhang et&#xa0;al.</ext-link>, shifts the focus to supersulfides, such as hydropersulfides (RSS<sub>n</sub>H) and polysulfides (RSS<sub>n</sub>R). These molecules, characterized by catenated sulfur chains, are now recognized as potent immunomodulators capable of managing inflammatory responses effectively. They are primarily generated through the activity of cysteinyl-tRNA synthetase (CARS), particularly the mitochondrial CARS2 isoform, and execute their functions through S-persulfidation. The authors highlight how supersulfide donors exert anti-inflammatory effects by suppressing NF-&#x3ba;B signaling, modulating the NLRP3 inflammasome, and blocking JAK/STAT pathways, which leads to the inhibition of interferon responses in macrophages. Furthermore, the authors discuss the development of various supersulfide donors designed to deliver RSS to specific tissues. These donors show promise in treating a range of conditions, including sepsis, rheumatoid arthritis, and metabolic-associated fatty liver disease (MAFLD). Moreover, the review examines the potential role of supersulfides in treating COVID-19 and influenza by inactivating viral proteases and dampening the &#x201c;cytokine storm&#x201d;.</p>
<p>The final review paper in this Research Topic, by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2026.1764165">Hirabayashi et&#xa0;al.</ext-link>, is dedicated to the enzymes that regulate intracellular RSS levels. The authors focus not only on the enzymes involved in the production of H<sub>2</sub>S and supersulfides including cystathionine &#x3b2;-synthase (CBS), cystathionine &#x3b3;-lyase (CSE), 3-mercaptopyruvate sulfurtransferase (3MST), and CARS&#x2014;but also on those responsible for their catabolism, namely sulfide:quinone oxidoreductase (SQOR), persulfide dioxygenase (ETHE1), and thiosulfate sulfurtransferase (TST). The manuscript provides a comprehensive overview of their roles in maintaining RSS homeostasis and their enzymatic reaction mechanisms. While this review is not exclusively focused on inflammatory processes, it provides valuable information regarding selective inhibitors targeting each of the individual enzymes involved in RSS regulation. As the authors emphasize, these inhibitors could serve as powerful tools for elucidating the biological functions of RSS in inflammation and may hold significant therapeutic potential.</p>
<p>The original paper by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1606408">Golenkina et&#xa0;al.</ext-link> explores how disulfide stress is linked to leukotriene synthesis. It is well-established that neutrophils are the primary immune cells recruited to the site of invading pathogens. When neutrophils interact with bacteria, they produce leukotriene B4 (LTB<sub>4</sub>), a powerful chemoattractant that, along with the principal bacterial chemoattractant i.e. N-formylmethionine-leucine-phenylalanine (fMLP), promotes the formation of neutrophil clusters around pathogens. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1606408">Golenkina et&#xa0;al.</ext-link> investigated the regulating role of H<sub>2</sub>S in neutrophil cellular responses using an experimental model of neutrophils interacting with <italic>Salmonella typhimurium</italic>. Their findings demonstrate that under conditions of disulfide stress, which occurs during neutrophil-bacteria interactions, the use of the H<sub>2</sub>S donor supports the synthesis of LTB<sub>4</sub>, with a subsequent increase in the accumulation of neutrophils in bacterial clusters. This discovery can be used to search for innovative therapeutic interventions in bacterial infection states using H<sub>2</sub>S donors.</p>
<p>The next interesting finding in this Research Topic is related to the role of SO<sub>2</sub> in mast cell activation-related diseases. It is known that mast cell degranulation is a critical step in allergic and inflammatory responses. Endogenous SO<sub>2</sub> is an essential regulator of mitochondrial activity and is involved in the inflammatory response; however, the mechanism underpinning its participation in mast cell degranulation remained unknown until recently. The study by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1369326">Song et&#xa0;al.</ext-link> elucidated that SO<sub>2</sub> inhibits mast cell degranulation via the sulfenylation of galectin-9 (Gal-9) at cysteine 74 under both physiological and IgE- and non-IgE-stimulated pathophysiological conditions. This study identifies Gal-9 as an important regulatory molecule for controlling immune cell activity, and a biological target for therapeutic interventions. The development of drugs that stimulate sulfenylation of Gal-9 might provide a novel treatment approach for mast cell activation-related diseases.</p>
<p>In conclusion, we believe that this Research Topic provides a profound exploration of the role of sulfur compounds in inflammation and offers a critical discussion of their therapeutic potential. In the published papers, the authors have presented the most up-to-date information on the roles of reactive sulfur species (RSS)&#x2014;primarily H<sub>2</sub>S, persulfides, polysulfides, and SO<sub>2</sub>&#x2014;in inflammatory diseases. It should be emphasized that the biological effects of RSS are bidirectional and context-dependent. Specifically, they can either promote or suppress immune responses, depending on their concentration and the cellular redox environment. These factors must be carefully considered in future research and in the establishment of dose-response relationships for clinical applications.</p>
</body>
<back>
<sec id="s1" sec-type="author-contributions">
<title>Author contributions</title>
<p>MI: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. TS: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. EL: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. MK: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p></sec>
<sec id="s3" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s4" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s5" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors&#xa0;and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Iciek</surname> <given-names>M</given-names></name>
<name><surname>Bilska-Wilkosz</surname> <given-names>A</given-names></name>
<name><surname>Kozdrowicki</surname> <given-names>M</given-names></name>
<name><surname>G&#xf3;rny</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Reactive sulfur species and their significance in health and disease</article-title>. <source>Biosci Rep</source>. (<year>2022</year>) <volume>42</volume>:<elocation-id>BSR20221006</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BSR20221006</pub-id>, PMID: <pub-id pub-id-type="pmid">36039860</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>H</given-names></name>
<name><surname>Lv</surname> <given-names>B</given-names></name>
<name><surname>Tang</surname> <given-names>C</given-names></name>
<name><surname>Du</surname> <given-names>J</given-names></name>
<name><surname>Jin</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>Sulfur dioxide: endogenous generation, biological effects, detection, and therapeutic potential</article-title>. <source>Antioxid Redox Signal</source>. (<year>2022</year>) <volume>36</volume>:<page-range>256&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/ars.2021.0213</pub-id>, PMID: <pub-id pub-id-type="pmid">34538110</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vignane</surname> <given-names>T</given-names></name>
<name><surname>Filipovic</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Emerging chemical biology of protein persulfidation</article-title>. <source>Rev Antioxid Redox Signal</source>. (<year>2023</year>) <volume>39</volume>:<fpage>19</fpage>&#x2013;<lpage>39</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/ars.2023.0352</pub-id>, PMID: <pub-id pub-id-type="pmid">37288744</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>H</given-names></name>
<name><surname>Lv</surname> <given-names>B</given-names></name>
<name><surname>Liu</surname> <given-names>K</given-names></name>
<name><surname>Du</surname> <given-names>J</given-names></name>
<name><surname>Jin</surname> <given-names>H</given-names></name>
<name><surname>Huang</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Sulfur dioxide controls M1 macrophage polarization by sulphenylation of prolyl hydroxylase 2 at cysteine 260</article-title>. <source>Free Radic Biol Med</source>. (<year>2025</year>) <volume>230</volume>:<fpage>33</fpage>&#x2013;<lpage>47</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2025.01.054</pub-id>, PMID: <pub-id pub-id-type="pmid">39892500</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>T</given-names></name>
<name><surname>Toyomoto</surname> <given-names>T</given-names></name>
<name><surname>Sawa</surname> <given-names>T</given-names></name>
<name><surname>Akaike</surname> <given-names>T</given-names></name>
<name><surname>Matsunaga</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Supersulfides: A promising therapeutic approach for autoinflammatory diseases</article-title>. <source>Microbiol Immunol</source>. (<year>2025</year>) <volume>69</volume>:<fpage>191</fpage>&#x2013;<lpage>202</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/1348-0421.13205</pub-id>, PMID: <pub-id pub-id-type="pmid">39956868</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited and reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/22645"> Pietro Ghezzi</ext-link>, Brighton and Sussex Medical School, United Kingdom</p></fn>
</fn-group>
</back>
</article>